RT @jsross119: Several years ago, @rgupta729, @thehowie and I showed that among FDA-approved, off-patent brand-name drugs in tablet or caps…
RT @jsross119: Several years ago, @rgupta729, @thehowie and I showed that among FDA-approved, off-patent brand-name drugs in tablet or caps…
RT @jsross119: Several years ago, @rgupta729, @thehowie and I showed that among FDA-approved, off-patent brand-name drugs in tablet or caps…
RT @jsross119: Several years ago, @rgupta729, @thehowie and I showed that among FDA-approved, off-patent brand-name drugs in tablet or caps…
RT @jsross119: Several years ago, @rgupta729, @thehowie and I showed that among FDA-approved, off-patent brand-name drugs in tablet or caps…
RT @jsross119: Several years ago, @rgupta729, @thehowie and I showed that among FDA-approved, off-patent brand-name drugs in tablet or caps…
RT @jsross119: Several years ago, @rgupta729, @thehowie and I showed that among FDA-approved, off-patent brand-name drugs in tablet or caps…
RT @jsross119: Several years ago, @rgupta729, @thehowie and I showed that among FDA-approved, off-patent brand-name drugs in tablet or caps…
Several years ago, @rgupta729, @thehowie and I showed that among FDA-approved, off-patent brand-name drugs in tablet or capsule formulation that were in monopolies or duopolies, median prices more than doubled after acquisition @JournalGIM https://t.co/NRS
RT @jsross119: @LeoBeletsky @gregggonsalves You can make it a data informed prediction: https://t.co/7O6dtKJWNe
@LeoBeletsky @gregggonsalves You can make it a data informed prediction: https://t.co/7O6dtKJWNe
RT @jsross119: When there is no/little generic competition, old (off-patent) drugs are more likely to have their prices raised (more than d…
RT @rgupta729: @SGottliebFDA remarks on forming drug import working group (https://t.co/9TN2F8Bqps) focus on old off-patent drugs with 1 ma…
RT @jsross119: When there is no/little generic competition, old (off-patent) drugs are more likely to have their prices raised (more than d…
RT @jsross119: When there is no/little generic competition, old (off-patent) drugs are more likely to have their prices raised (more than d…
RT @jsross119: When there is no/little generic competition, old (off-patent) drugs are more likely to have their prices raised (more than d…
When there is no/little generic competition, old (off-patent) drugs are more likely to have their prices raised (more than doubled) after market acquisition; this is not R&D, it demonstrates how healthcare is not a true market (if you need a drug, you
@SGottliebFDA remarks on forming drug import working group (https://t.co/9TN2F8Bqps) focus on old off-patent drugs with 1 manufacturer & facing price increases. We know acquisitions can contribute to price increases for these drugs: https://t.co/makiFQ
@JeffFager Acthar @60Minutes story brings together so many threads of drug pricing debacle, incl. unapproved drugs https://t.co/lH1bKZYwyi, acquisition impact https://t.co/NRSIOjUE6G, off-label spending https://t.co/18Xk83wcUr, industry $$ to docs https://
RT @YaleSPH: The Impact of Off-Patent #Drug Acquisitions on Prices. https://t.co/qw0RxfIkXL @YaleHPM @jsross119 @thehowie
RT @YaleSPH: The Impact of Off-Patent #Drug Acquisitions on Prices. https://t.co/qw0RxfIkXL @YaleHPM @jsross119 @thehowie
The Impact of Off-Patent #Drug Acquisitions on Prices. https://t.co/qw0RxfIkXL @YaleHPM @jsross119 @thehowie
Hmmm sure but using the samle 'tools'??? https://t.co/qqPgOmDEOY
RT @NatureBiotech: Biopharma singled out Turing Pharma's Shkreli as a bad actor/outlier. Think again: J Gen Intern Med study suggests Turin…
RT @NatureBiotech: Biopharma singled out Turing Pharma's Shkreli as a bad actor/outlier. Think again: J Gen Intern Med study suggests Turin…
RT @NatureBiotech: Biopharma singled out Turing Pharma's Shkreli as a bad actor/outlier. Think again: J Gen Intern Med study suggests Turin…
RT @NatureBiotech: Biopharma singled out Turing Pharma's Shkreli as a bad actor/outlier. Think again: J Gen Intern Med study suggests Turin…
I was hoping Pharma-Bro was a one-off. Looks like he isn't... https://t.co/necPTkCfEU https://t.co/necPTkCfEU
no shit https://t.co/ANcuHRyjjr
Biopharma singled out Turing Pharma's Shkreli as a bad actor/outlier. Think again: J Gen Intern Med study suggests Turing’s drug price hike after acquisition not isolated event. Caveat: price hikes not significantly higher https://t.co/nrZG6aiL8z #NBTNew
RT @HealthLawAdamH: This is a neat (and remarkably concise) study on consequences of acquisition of off-patent drugs. #OffPatentTrolls http…
This is a neat (and remarkably concise) study on consequences of acquisition of off-patent drugs. #OffPatentTrolls https://t.co/IlY4xlfGB0
@jgreene2 @US Tell them about this paper, hot off the press! https://t.co/makiFQYotj
RT @JCavallo972: Acquisitions are 1 of the factors driving pharmaceutical price increases https://t.co/DEOlVaeVBo
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @JCavallo972: Acquisitions are 1 of the factors driving pharmaceutical price increases https://t.co/DEOlVaeVBo
RT @JCavallo972: Acquisitions are 1 of the factors driving pharmaceutical price increases https://t.co/DEOlVaeVBo
Acquisitions are 1 of the factors driving pharmaceutical price increases https://t.co/DEOlVaeVBo
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
RT @jsross119: Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests th…
Our study on impact of off-patent drug acquisitions finds median price more than doubles after acquisition, also suggests that acquired brand-name and generic drugs priced 2.5x higher (not statistically significant, but small sample) @JournalGIM https://t.